Investigational drug · Phase 3
Picankibart
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Psoriatic Arthritis, Plaque Psoriasis.
Phase 3Last checked: Nov 19, 2026Latest source record: Mar 25, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
4
Any phase or sponsor naming "Picankibart"
First trial start
2025
May 27, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Picankibart", any sponsor or status.
Conditions studied
As listed on its trial records.
- Psoriatic Arthritis
- Plaque Psoriasis
Approved drugs for the same conditions: Plaque psoriasis · Psoriatic arthritis · Immunology and inflammation
Largest trials
Live from ClinicalTrials.gov: studies naming "Picankibart" as an intervention, largest first.
- A Study of Switching to Picankibart in Chinese Patients With Plaque Psoriasis With an Inadequate Response to Interleukin-17 Monoclonal Antibody TherapyPivotal-lookingActive, not recruiting
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.Industry
NCT06945107 · 308 participants · Start May 27, 2025 · Primary completion Jun 7, 2026
Drug: Picankibart; Secukinumab and 2 more · For: Plaque Psoriasis
Sites: Jinan, China
- A Study of Picankibart in Patients With Active Psoriatic ArthritisPivotal-lookingRecruiting
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.Industry
NCT07295509 · 222 participants (planned) · Start Dec 18, 2025 · Primary completion Dec 31, 2029
Drug: Picankibart · For: Psoriatic Arthritis
Sites: Hangzhou, China
- A Study to Evaluate Efficacy and Safety of IBI112 in Adolescent Participants With Moderate to Severe Plaque PsoriasisPivotal-lookingRecruiting
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.Industry
NCT07265284 · 104 participants (planned) · Start Dec 3, 2025 · Primary completion Sep 30, 2026
Drug: IBI112; placebo · For: Psoriasis
Sites: Beijing, China
- Picankibart in Palmoplantar PustulosisRecruiting
Xijing HospitalAcademic, hospital or other
NCT07552454 · 60 participants (planned) · Start Apr 15, 2026 · Primary completion Oct 15, 2027
Drug: Picankibart · For: Palmoplantar Pustulosis
Sites: Xi'an, China
Newest research
PubMed records naming it or its code names, newest first.
- Response to the letter by Ghanim et al, "Comment on Gao et al's 'A multicenter, randomized, double-blinded, placebo-controlled phase III trial to evaluate efficacy and safety of picankibart in moderate-to-severe plaque psoriasis'".
Shi Y · J Am Acad Dermatol 2026
- Comment on Gao et al's "A multicenter, randomized, double-blinded, placebo-controlled phase III trial to evaluate efficacy and safety of picankibart in moderate-to-severe plaque psoriasis".
Ghanim D, Ghebrial M, Tognaccini C, et al. · J Am Acad Dermatol 2026
- Highlights of the 2026 European Crohn's and Colitis Conference: redefining the IBD care continuum.
Al-Hindawi A, Siegel A, Miranda CJ, et al. · Crohns Colitis 360 2026
- A multicenter, randomized, double-blinded, placebo-controlled phase III trial to evaluate efficacy and safety of picankibart in moderate-to-severe plaque psoriasis.
Gao Y, Qin L, Li Y, et al. · J Am Acad Dermatol 2026
- Efficacy and Safety of Switching to Picankibart from Non-interleukin-23 Subunit p19 Inhibitors in Patients with Plaque Psoriasis: A Multicenter, Open-Label, Phase 2 Trial.
Yang Q, Yang B, Gu H, et al. · Adv Ther 2026
Also in development for Psoriatic Arthritis
- ZasocitinibTAK- 279, NDI-034858Phase 317 trials
Takeda · Plaque Psoriasis, Psoriatic Arthritis, Crohn's Disease
- MK-7240PRA023, TulisokibartPhase 310 trials
Merck & Co. · Ulcerative Colitis, Psoriatic Arthritis, Crohn's Disease
- LutikizumabABT-981Phase 38 trials
AbbVie · Hidradenitis Suppurativa, Atopic Dermatitis, Rheumatoid Arthritis
- TQH3906Phase 34 trials
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · Psoriasis, Systemic Lupus Erythematosus, Psoriatic Arthritis
- SHR-1314Phase 33 trials
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Active Non-radiographic Axial Spondyloarthritis, Children and Adolescents Aged 6 to 18 With Moderate-to-Severe Plaque Psoriasis, Psoriatic Arthritis
- SHR0302Phase 32 trials
Jiangsu HengRui Medicine Co., Ltd. · Non-segmental Vitiligo, Psoriatic Arthritis
- ABBV-701Phase 22 trials
AbbVie · Crohn's Disease, Ulcerative Colitis, Psoriatic Arthritis
- SPY002-072SPY072Phase 22 trials
Spyre Therapeutics, Inc. · Rheumatoid Arthritis, Psoriatic Arthritis, Axial Spondyloarthritis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.